**Castor™ Gains CFDA Approval**

Castor™ Branched Aortic Stent-Graft System ("Castor™"), in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd ("MicroPort™") obtained the regulatory approval from China Food and Drug Administration ("CFDA"). It is the fourth device of MicroPort™ that gained the CFDA approval through the CFDA Green Path for innovative medical devices.

Castor™ is the first endovascular device used to preserve the branch artery while repair the thoracic aorta. Its unique "unibody design" could accommodate diverse arch anatomy. It is also the world's first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery and 20mm distal to the left carotid artery. Castor™ adopted the "unibody design", which is sewing the main body and branch stent together to make it possible to deploy and release at the same time. This design innovatively accomplishes deployment and positioning of the unibody branched stent graft, achieving low endoleak rate and better branch artery patency, which reduces the operative trauma and improves safety during the procedure. Castor™ also employs several unique designs, such as kink-free outer sheath design, soft sheath design with excellent arch crossability, and branch stent sheath.

Though endovascular repair has become the main method to treat aortic dilation diseases, thoracic aortic dissection involving aortic arch branch artery, such as left subclavian artery, is still the relative contraindication of endovascular repair due to lack of suitable endovascular prosthesis. The launch of Castor™ marks a significant step forward in using endovascular repair to treat aortic arch, making breakthroughs in a key area clinicians have spent many years to research and explore.
MicroPort® EP
Obtains CFDA Approval for OptimAblate™ Irrigation Pump


The OptimAblate™ Irrigation Pump is a special device designed for the RF ablation procedure of cardiac arrhythmias, to be used with the specialized tubing set. When used with the RF generator, the irrigation pump cools down the ablating process by perfusing saline to irrigated ablation catheters at certain flow rate, and thereby to achieve deep ablation, improve success rate and reduce thrombosis.
Firefighter™ PTCA
Balloon Dilatation Catheter
Gains Regulatory Approval in Brazil

On June 26, Firefighter™ PTCA Balloon Dilatation Catheter ("Firefighter™ PTCA"), in-house developed by Shanghai MicroPort Medical (Group) Co ("MicroPort"), received approval from Brazil’s National Health Surveillance Agency.

Firefighter™ PTCA is used in percutaneous transluminal coronary angioplasty ("PTCA") for coronary dilatation. It can be used in combination with MicroPort’s in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"). As the new generation of high-end balloon catheter MicroPort® elaborately designed after JIVE™ PTCA and FOXTROT™ PRO PTCA Balloon Dilatation Catheters, Firefighter™ PTCA has much smaller balloon crossing profile and softer material compared to competitors’ products, allowing excellent crossability through stenotic and tortuous lesions and make it possible for two balloon catheters to be accommodated in a 5F guiding catheter, which facilitates physicians to go kissing balloon strategy and other complex operations. The Firefighter™ PTCA that gained regulatory approval in Brazil this time has a total of 43 specifications, covering 12 diameters (1.0mm-4.0mm), and four lengths (6mm, 10mm, 15mm and 20mm).
MPSC Signs Investment Agreement with Zenomics to Promote the Translation of "Smart" Insulin Devices

MicroPort Scientific Corporation ("MPSC") and its subsidiary recently signed an investment agreement with US-based Zenomics, Inc., announcing $5.8 million infusion of capital into Zenomics by MPSC, and in exchange MPSC obtains a 21% ownership stake in Zenomics. Meanwhile, Shanghai MicroPort Lifesciences Co., Ltd. ("MicroPort® Lifesciences"), a subsidiary of MPSC, signed a Technology License Agreement with Zenomics which provides MicroPort® Lifesciences with intellectual property rights, such as patents and know-how, related with the Drug-Release Platform of Zenomics.

The microneedles – hundreds of which fit onto the coin-sized patch or other smart device platform – feature microscopic storage units for insulin and glucose-sensing components. When blood sugar levels get too high, the microneedles automatically release insulin, combining the testing with the insulin injection in a pain-free and perfectly timed manner that requires little to no effort by the person wearing the device.

"The smart insulin delivery is inspired by the interaction between glucose and glucose-sensitive moiety, which is integrated into a transcutaneous patch. This smart patch can sense increased blood sugar level and subsequently release insulin in a fast manner, and can reduces the risk of hypoglycemia," said Professor Gu, Co-founder and Chairman of Zenomics. "In addition, the technology is painless and it also lessens human error, so that you receive a more accurate blood-sugar controlling."
**MPSC 2017 Annual General Meeting Held**

MPSC 2017 Annual General Meeting ("AGM") was held on June 20 in its Shanghai headquarters. The meeting was chaired by Dr. Zhaohua Chang, Chairman, Executive Director and Chief Executive Officer of MPSC. According to Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited, all of the 12 ordinary resolutions were taken by poll. All the proposed resolutions were passed by votes representing more than half of the total number of votes held by the attending shareholders and proxies having valid voting rights.

During the meeting, Dr. Zhaohua Chang, MPSC Chief Marketing Officer Bo Peng, MPSC Chief Finance Officer Martin Sun, MPSC Chief Technology Officer Dr. Qiyi Luo, Jonathan Chen, MPSC Executive Vice President of International Operations and Investor Relations, and Aurelio Sahagun, President of MicroPort Orthopedics Inc, answered questions raised by shareholders in terms of business condition, competitive landscape, and future plans of the company.

According to poll results, Dr. Zhaohua Chang was re-elected as Executive Director of MPSC, Norihiro Ashida and Hiroshi Shirafuji were re-elected as non-executive directors of the company, and Chunyang Shao was re-elected as independent non-executive director of MPSC. Meanwhile, the AGM approved a final dividend of HK$1.9 cent per share in the capital of the company for the year ended 31 December 2016.
MicroPort® Endovascular Attends SJVF-2017

From June 23 to June 25, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort Endovascular") attended the Sixth Shanghai JiaoTong University Vascular Disease Forum ("SJVF-2017") held in Shanghai. During the forum, Professor Jing pointed out China is leading the world in endovascular treatment of aortic arch with techniques such as fenestration, chimney, in-situ fenestrated technique, and branched stent technique. One case in point is Castor™, the first successfully translated branched endo-prosthesis involving aortic arch in the world, which is jointly developed by Changhai Hospital and MicroPort Endovascular. Castor™ is also the world’s first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery. According to Professor Jing, Castor™ had launched a multi-center study involving 11 clinical centers in China and has completed a one-year follow-up which achieved good results. The study is the first perspective, multi-center clinical study for original device in the vascular field.
MicroPort® OrthoRecon Project Listed in National Key R&D Plan

The project "Research on a Minimal Invasive, High Efficiency Orthopedic Robotic System," co-launched by Suzhou MicroPort OrthoRecon Co., Ltd. ("MicroPort®OrthoRecon"), was listed in the National Key Research & Development ("R&D") Plan, falling into the category of "Digital Diagnostic Equipment R&D," according to the announcement regarding the arrangement of five key categories (including Stem Cells and Translational Research) of the National Key R&D Plan for the Year 2017 released by the China National Center for Biotechnology Development under the Ministry of Science and Technology.

Aiming to seize the opportunity of the new round of revolution in the healthcare industry, the category of "Digital Diagnostic Equipment R&D" is being oriented on early diagnosis, accurate diagnosis, minimally invasive treatment, precise treatment, while focused on 10 key strategic products such as multimodal molecular imaging and large-scale radiotherapy equipment. It is expected to systematically strengthen the key technology research, push the development of cutting-edge technologies, facilitate the improvement of detecting technique, standardized systems, application solution and pilot application evaluation research, and thereby to speed up the integration of the production and innovation of China's medical device industry and help China's digital diagnostic equipment industry ascend into the international advanced level. The project "Research on a Minimal Invasive, High Efficiency Orthopedic Robotic System" is a four-year project.
MicroPort® Attends China and CEEC Health Economy Conference and Exhibition

On June 20, Shanghai MicroPort Medical (Group) Co., Ltd ("MicroPort") attended the China and Central and Eastern European Countries ("CEEC") Health Economy Conference and Exhibition as one of the eight representatives of innovative high-tech enterprises in China. The conference was hosted during the Third China-CEEC Health Ministers Meeting held in Budapest of Hungary from June 18 to June 20.

Director of the National Health and Family Planning Commission of China Bin Li, Minister of National Economy of Hungary Mihály Varga and other officials in CEEC visited MicroPort booth. Dr. Linda Lin, First Vice President of MicroPort International Business, introduced to them MicroPort’s development history, business segments, and product portfolio with the emphasis on its international business development. Physicians and local medical device agencies showed great interest in MicroPort’s in-house developed Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk") and cardiac electrophysiological devices. They said, products as high quality and high cost-effective as Firehawk will have unlimited local market demand.
**MicroPort® Attends OCC 2017**

From May 25 to May 28, MicroPort® attended the 11th Oriental Congress of Cardiology ("OCC 2017") in Shanghai Expo Center and hosted a satellite meeting and a case contest.

On May 27, MicroPort® hosted a satellite meeting – "The Rhythm of MicroPort*: the Latest Clinical Data of TARGET Series Studies,** Professor Bo Xu of Fuwai Hospital of Chinese Academy of Medical Sciences released the three-month Optical Computerized Tomography ("OCT") data from the TARGET All Comer trial for Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk™"). TARGET All Comer is the first post-market randomized trial in 10 European countries for Firehawk*. The TARGET All Comer study started in December 2015 and completed its enrollment in October 2016. A total of 1,656 patients were enrolled, including pre-specified 50 in the OCT sub-study and 176 in a QCA sub-study (13-month follow-up). During the meeting, Professor Jinjie Dai of Shanghai Chest Hospital, Professor Huimin Liu of the Second Affiliated Hospital of Harbin Medical University, and Professor Kun Wang of Nanjing Drum Tower Hospital also shared some cases using Firehawk* to further demonstrate its excellent performance in clinical application, which was well received by experts in attendance.
MicroPort® OrthoRecon Attends the 5th Chinese Knee Society Conference

From June 16 to June 18, MicroPort® OrthoRecon attended the 5th Chinese Knee Society Conference held in Xi'an, Shaanxi Province and hosted a satellite meeting.

As a premier event in China’s knee surgery field, the 5th Chinese Knee Society Conference invited a great many of industry experts to exchange ideas on hot topics related with the latest advancement and philosophies in the knee surgery field by case studies and operation demonstrations, in the hope of achieving expert consensus regarding the development of China’s knee surgery field. Professor Wu Haishan introduced in-detail the design rationale of EVOLUTION® Medial-Pivot Knee System (“EVOLUTION®”). EVOLUTION® features ball-in-socket articulation which enhances stability and allows the prosthesis to move and feel more like a normal knee, to enhance stability and comfort for patients in their daily life.
MicroPort® OrthoRecon Hosts
Hip Replacement Live Surgery Symposium

On June 8, MicroPort® OrthoRecon hosted a Hip Replacement Live Surgery Symposium in West China Hospital of Sichuan University, aiming to provide a platform for orthopedic experts in Southwest China to exchange ideas on SuperPath™ Micro-posterior Total Hip Arthroplasty ("SuperPath™"). Professor Bing Xia of Zhejiang Provincial People's Hospital delivered a speech on SuperPath™ and shared his opinion about minimally invasive surgery, and he thinks minimally invasive surgery is becoming a major method to facilitate fast return to function, and SuperPath™ technique represents an important development trend of the minimally invasive surgery. The live surgery afterwards enabled the trainees to fully understand the key points and difficulties of SuperPath™ technique.
MicroPort® OrthoRecon Hosts SuperPath™ Training Course

On June 4, MicroPort® OrthoRecon hosted a training course “Fast to Full Function: SuperPath™ Train the Trainer Course” in Shanghai. The creator of SuperPath™ Professor Jimmy Chow and his father Professor James Chow, former President of Arthroscopy Association of North America were invited to the course.

Professor Chow introduced his follow-up study and said: "All of the post-operational dislocation rate, deep vein thrombus ('DVT') rate and deep infection rate of patients undergoing SuperPath™ technique are less than 1%. SuperPath™ can be used not only in primary hip arthroplasty but also in the revision operations. All of my revision cases are started with SuperPath™, and less than 20% need transferring to traditional approach." In addition, Professor Jimmy Chow pointed out, currently MicroPort® OrthoRecon offers two versions of femoral prosthesis - monoblock and modular stem - with the same design rationale, profile and instrument, which makes them the best prosthesis to work with SuperPath™ technique.
MicroPort® EP Attends CSA 2017

From June 8 to June 10, MicroPort® EP attended the 2017 Annual Meeting of the Heart Rhythm Special Committee of Chinese Medical Doctor Association ("CSA 2017") held in Hangzhou, and hosted a satellite meeting "Columbus™: Navigation for the Heart." During the meeting, Professor Yuchuan Wang of Peking University First Hospital shared a case of treating left posterior fascicular ventricular tachycardia with Columbus™. Professor Wang said, he was impressed by the stable performance of Columbus™, and its full curve display facilitates the physicians to observe the positioning of the catheter and treatment effect. Professor Lanyan Guo of Xijing Hospital said, according to her clinical experience, the domestically made 3D mapping system can largely reduce the X-ray exposure and improve the ablation effect. She also expressed her expectation that the domestically made system can deliver more updated function to keep up with the imported products. Professor Songhai Wen of Southeast Guizhou People's Hospital compared Columbus™ with several competitors' products in the market such as Carto 3 and Ensite Velocity and emphasized the benefits of the domestically made system and its matching catheter for patients, such as lowered treatment cost.
MicroPort® NeuroTech Attends CSIR 2017

From June 15 to June 18, MicroPort NeuroTech (Shanghai) Co., Ltd. (“MicroPort® NeuroTech”) attended the 14th Scientific Meeting of Chinese Society of Interventional Radiology (“CSIR 2017”) in Zhengzhou, Henan Province. In the intracranial aneurysm session of the conference, Professor Chun Fang of Shanghai Tongji Hospital shared the clinical experience in using MicroPort® NeuroTech’s WILLIS® Intracranial Stent Graft System (“WILLIS”™) to treat cerebral aneurysm, and spoke highly of the excellent performance of WILLIS®. Plenty professors had in-depth discussion with the R&D staff regarding the performance and technologies of WILLIS® and APOLLO Intracranial Stent System. They also expressed their expectations on the upcoming innovative products of MicroPort® NeuroTech such as Tubridge® Vascular Reconstruction Device.
MicroPort® Co-organizes Training Program of 2017 Coronary Interventional Treatment Training Center – Shanghai Division

The training program of the 2017 Coronary Interventional Treatment Training Center – Shanghai Division was recently launched. This training program was jointly held by Shanghai Cardiac Interventional Quality Control Center and 11 Shanghai-based hospitals, and MicroPort* was the sole strategic partner. The training program aims to leverage the best faculty in Shanghai to teach existing and potential interventional physicians the most accurate and advanced theories and operative techniques and meanwhile to provide trainees with a platform for academic exchange. This training program was jointly launched by Shanghai Cardiac Interventional Quality Control Center, Zhongshan Hospital of Fudan University, Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai Chest Hospital, Renji Hospital of Shanghai Jiao Tong University School of Medicine, Changzheng Hospital of the Second Military Medical University, Shanghai General Hospital, Shanghai Sixth People's Hospital, Shanghai Tenth People's Hospital, Xinhua Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai Oriental Hospital of Tongji University. A total of 104 doctors took part in the training program.
For more information, please contact:

**Martin Sun**  
Chief Financial Officer  
MicroPort Scientific Corporation  
Tel: (86)(21) 38954600  
Email: ir@microport.com

**Leanne Li**  
Board Secretary & VP of Corporate General Affairs  
MicroPort Scientific Corporation  
Tel: (86)(21) 38954600  
Email: ir@microport.com